BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boston Children's Hospital Release: After Gastric Bypass, Small Intestine Reprograms to Regulate Glucose and Resolve Type 2 Diabetes


7/26/2013 9:05:14 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Researchers observe new mechanism for diabetes resolution, spurring more opportunities for anti-diabetic therapies

BOSTON, July 25, 2013 /PRNewswire-USNewswire/ -- Though existing research has shown gastric bypass surgery resolves type 2 diabetes, the reason has remained unclear. A research team, led by Nicholas Stylopoulos, MD, Boston Children's Hospital'sDivision of Endocrinology, has identified the small intestinewidely believed to be a passive organas the major contributor to the body's metabolism, based on a study in rats. The report will appear in Science on July 26, 2013.

Weight loss and improved diabetes often go hand-in-hand, but type 2 diabetes often gets resolved even before weight loss occurs after gastric bypass. To investigate why this happens, Stylopoulos and his team spent one year studying rats, and observed that after gastric bypass surgery, the small intestine changes the way it processes glucose. The team saw the intestine using and disposing of glucose; thereby regulating blood glucose levels in the rest of the body and helping to resolve type 2 diabetes.

"We have seen type 2 diabetes resolve in humans after gastric bypass, but have never known why," says Stylopoulos. "People have been focusing on hormones, fat and muscle, but we have shown in this study that the answer lies somewhere in the small intestine most of the time."

Gastric bypass surgery, a weight loss treatment typically reserved for severely obese patients, reroutes food into the smaller pouch of the stomach and bypasses the rest of the stomach and duodenum. Before gastric bypass, intestines typically do not contain a specific transporter called GLUT-1, which is responsible for removing glucose from circulation and utilizing it within the organ. After gastric bypass, the researchers found that the intestine reprograms itself to contain GLUT-1, taking glucose from circulation and disposing of it, swiftly stabilizing blood glucose levels in the rest of the body.

"Previously, we had not considered the intestine as a major glucose-utilizing organ. We have found this process is exactly what happens after surgery," says Stylopoulos.

Based on their findings, Stylopoulos and his colleagues found type 2 diabetes was resolved in 100 percent of the rats that underwent gastric bypass. Sixty-four percent of type 2 diabetes was resolved by the intestine, and the researchers hypothesize that the other 36 percent may be due to weight loss or other factors.

These findings pave the way for future investigations of how to create a medical pathway to mimic the intestine's reprogramming without the surgery. "With further research, we may find ways to bypass the bypass," says Stylopoulos. "The results of our study are promising because, unlike the brain and other organs, intestines are easily accessible. Furthermore, since cells in the intestine have such a short lifespan, we can easily study and pharmacologically manipulate them to use glucose, without long-term problems."

Nima Saeidi PhD, Luca Meoli, PhD, and Eirini Nestoridi, MD, are co-lead authors on this study. This research was supported with funds from the National Institutes of Health and the Division of Endocrinology, Department of Medicine and the Clinical and Translational Executive Committee at Boston Children's Hospital.

Boston Children's Hospitalis home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 13 members of the Institute of Medicine and 14 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395 bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children's, visit: http://vectorblog.org.

CONTACT: Cyndi Lepore
Boston Children's Hospital
617-919-3110
cynthia.lepore@childrens.harvard.edu

SOURCE Boston Children's Hospital



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES